215 related articles for article (PubMed ID: 30688000)
1. Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline?
Funaki K; Nakajima S; Noda Y; Wake T; Ito D; Yamagata B; Yoshizaki T; Kameyama M; Nakahara T; Murakami K; Jinzaki M; Mimura M; Tabuchi H
Psychogeriatrics; 2019 Jul; 19(4):325-332. PubMed ID: 30688000
[TBL] [Abstract][Full Text] [Related]
2. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
[TBL] [Abstract][Full Text] [Related]
3. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.
Kuhn E; Moulinet I; Perrotin A; La Joie R; Landeau B; Tomadesso C; Bejanin A; Sherif S; De La Sayette V; Desgranges B; Vivien D; Poisnel G; Chételat G
Alzheimers Res Ther; 2019 Jul; 11(1):61. PubMed ID: 31286994
[TBL] [Abstract][Full Text] [Related]
4. Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study.
Hong YJ; Ho S; Jeong JH; Park KH; Kim S; Wang MJ; Choi SH; Yang DW;
Alzheimers Res Ther; 2023 Aug; 15(1):132. PubMed ID: 37550761
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Limitations of rCBF-SPECT in the Diagnosis of Alzheimer's Disease With Amyloid-PET.
Takahashi M; Tada T; Nakamura T; Koyama K; Momose T
Am J Alzheimers Dis Other Demen; 2019 Aug; 34(5):314-321. PubMed ID: 30966759
[TBL] [Abstract][Full Text] [Related]
6. The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline.
Sanabria A; Alegret M; Rodriguez-Gomez O; Valero S; Sotolongo-Grau O; Monté-Rubio G; Abdelnour C; Espinosa A; Ortega G; Perez-Cordon A; Gailhajanet A; Hernandez I; Rosende-Roca M; Vargas L; Mauleon A; Sanchez D; Martin E; Rentz DM; Lomeña F; Ruiz A; Tarraga L; Boada M;
Sci Rep; 2018 Feb; 8(1):3828. PubMed ID: 29491481
[TBL] [Abstract][Full Text] [Related]
7. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI).
de Rojas I; Romero J; Rodríguez-Gomez O; Pesini P; Sanabria A; Pérez-Cordon A; Abdelnour C; Hernández I; Rosende-Roca M; Mauleón A; Vargas L; Alegret M; Espinosa A; Ortega G; Gil S; Guitart M; Gailhajanet A; Santos-Santos MA; Moreno-Grau S; Sotolongo-Grau O; Ruiz S; Montrreal L; Martín E; Pelejà E; Lomeña F; Campos F; Vivas A; Gómez-Chiari M; Tejero MA; Giménez J; Pérez-Grijalba V; Marquié GM; Monté-Rubio G; Valero S; Orellana A; Tárraga L; Sarasa M; Ruiz A; Boada M;
Alzheimers Res Ther; 2018 Nov; 10(1):119. PubMed ID: 30497535
[TBL] [Abstract][Full Text] [Related]
8. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
9. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project.
Timmers T; Ossenkoppele R; Verfaillie SCJ; van der Weijden CWJ; Slot RER; Wesselman LMP; Windhorst AD; Wolters EE; Yaqub M; Prins ND; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BNM
Neurobiol Aging; 2019 Jul; 79():50-58. PubMed ID: 31026622
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.
Caprioglio C; Ribaldi F; Visser LNC; Minguillon C; Collij LE; Grau-Rivera O; Zeyen P; Molinuevo JL; Gispert JD; Garibotto V; Moro C; Walker Z; Edison P; Demonet JF; Barkhof F; Scheltens P; Alves IL; Gismondi R; Farrar G; Stephens AW; Jessen F; Frisoni GB; Altomare D;
JAMA Netw Open; 2023 Jan; 6(1):e2250921. PubMed ID: 36637820
[TBL] [Abstract][Full Text] [Related]
11. Self-reported confusion is related to global and regional β-amyloid: data from the Women's healthy ageing project.
McCluskey GE; Yates P; Villemagne VL; Rowe C; Szoeke CEI
Brain Imaging Behav; 2018 Feb; 12(1):78-86. PubMed ID: 28108945
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults.
Hollands S; Lim YY; Buckley R; Pietrzak RH; Snyder PJ; Ames D; Ellis KA; Harrington K; Lautenschlager N; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P
J Alzheimers Dis; 2015; 43(2):677-86. PubMed ID: 25114076
[TBL] [Abstract][Full Text] [Related]
13. Relative impact of amyloid-β, lacunes, and downstream imaging markers on cognitive trajectories.
Kim HJ; Yang JJ; Kwon H; Kim C; Lee JM; Chun P; Kim YJ; Jung NY; Chin J; Kim S; Woo SY; Choe YS; Lee KH; Kim ST; Kim JS; Lee JH; Weiner MW; Na DL; Seo SW
Brain; 2016 Sep; 139(Pt 9):2516-27. PubMed ID: 27329772
[TBL] [Abstract][Full Text] [Related]
14. Subjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly.
Vogel JW; Varga Doležalová M; La Joie R; Marks SM; Schwimmer HD; Landau SM; Jagust WJ
Neurology; 2017 Nov; 89(19):2002-2009. PubMed ID: 28986416
[TBL] [Abstract][Full Text] [Related]
15. Early detection of amyloid load using
Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M
Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598
[TBL] [Abstract][Full Text] [Related]
16. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
Ong KT; Villemagne VL; Bahar-Fuchs A; Lamb F; Langdon N; Catafau AM; Stephens AW; Seibyl J; Dinkelborg LM; Reininger CB; Putz B; Rohde B; Masters CL; Rowe CC
J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):431-6. PubMed ID: 24970906
[TBL] [Abstract][Full Text] [Related]
17. Association of Subjective Memory Complaints with the Left Parahippocampal Amyloid Burden in Mild Cognitive Impairment.
Choo IH; Chong A; Chung JY; Kim H
J Alzheimers Dis; 2019; 72(4):1261-1268. PubMed ID: 31707367
[TBL] [Abstract][Full Text] [Related]
18. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
19. Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer's disease.
Verdile G; Laws SM; Henley D; Ames D; Bush AI; Ellis KA; Faux NG; Gupta VB; Li QX; Masters CL; Pike KE; Rowe CC; Szoeke C; Taddei K; Villemagne VL; Martins RN;
Mol Psychiatry; 2014 Jan; 19(1):69-75. PubMed ID: 23089633
[TBL] [Abstract][Full Text] [Related]
20. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
